Since the important roles of SGLT2 for renal glucose reabsorption and systemic glucose homeostasis in the human body were elucidated, the inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes mellitus. Here, SLC5A2 is linked to type 2 diabetes mellitus.